Table 1.

Summary of the study outcome and measures

Primary endpoint

Change in PMR in the primary lesion measured by CMR imaging

Secondary endpoint

Change in PMR in all lesions measured by CMR imaging  Percentage change in PMR in the primary lesion measured by CMR imaging  Percentage change in PMR in all lesion measured by CMR imaging  Changes in Hounsfield units, plaque volume, vessel area, and plaque area in the primary lesion measured by CTA  Changes in Hounsfield units, plaque volume, vessel area, and plaque area in all lesions measured by CTA  Percentage changes in Hounsfield units, plaque volume, vessel area, and plaque area in the primary lesion measured by CTA  Percentage changes in Hounsfield units, plaque volume, vessel area, and plaque area in all lesions measured by CTA

Other endpoint

Changes and percentage changes in triglycerides, total cholesterol, LDL-cholesterol, HDL-cholesterol, non-HDL-cholesterol, VLDL-cholesterol, remnant-like cholesterol, LPL activity, and high-sensitivity C-reactive protein  Changes and percentage changes in small, dense LDL and mean LDL particle diameter  Changes and percentage changes in EPA, DHA, AA, EPA/AA ratio, and omega-3 index (weight percentage of eicosapentaenoic acid [EPA, C20:5ω3] and docosahexaenoic acid [DHA, C20:6ω3] in total fatty acids out of all lipids)  Changes and percentage changes in leptin and adiponectin

AA arachidonic acid, CMR cardiac magnetic resonance, CTA computed tomography angiography, HDL high-density lipoprotein, LDL low-density lipoprotein, LPL lipoprotein lipase, PMR plaque-to-myocardium signal intensity ratio, VLDL very-low density lipoprotein